High vaccination efficiency of low-affinity epitopes in antitumor immunotherapy. - Wikidata - awgldk - TriplyDB

High vaccination efficiency of low-affinity epitopes in antitumor immunotherapy.

High vaccination efficiency of low-affinity epitopes in antitumor immunotherapy.

http://www.wikidata.org/entity/Q35631830

about

Telomerase peptide vaccination of patients with non-resectable pancreatic cancer: A dose escalating phase I/II study Optimized tumor cryptic peptides: the basis for universal neo-antigen-like tumor vaccines Identification and enhancement of HLA-A2.1-restricted CTL epitopes in a new human cancer antigen-POTE.Upregulated human telomerase reverse transcriptase (hTERT) expression is associated with spinal chordoma growth, invasion and poor prognosis.Dendritic cell mediated delivery of plasmid DNA encoding LAMP/HIV-1 Gag fusion immunogen enhances T cell epitope responses in HLA DR4 transgenic mice Highly optimized DNA vaccine targeting human telomerase reverse transcriptase stimulates potent antitumor immunity.Telomerase as a tumor-associated antigen for cancer immunotherapy Peptide-pulsed dendritic cells have superior ability to induce immune-mediated tissue destruction compared to peptide with adjuvant CD25 blockade depletes and selectively reprograms regulatory T cells in concert with immunotherapy in cancer patients Vaccine-induced Aβ-specific CD8+ T cells do not trigger autoimmune neuroinflammation in a murine model of Alzheimer's disease.Cytotoxic T cells generated against heteroclitic peptides kill primary tumor cells independent of the binding affinity of the native tumor antigen peptide.HLA class I transgenic mice: development, utilisation and improvement.Immunity for tumors and microbes after autotransplantation: if you build it, they will (not) come.Towards a therapeutic breast cancer vaccine: the next steps.The tumor-draining lymph node as an immune-privileged site.Telomerase-based immunotherapy of cancer.'1-8 interferon inducible gene family': putative colon carcinoma-associated antigens.Breast cancer immunobiology driving immunotherapy: vaccines and immune checkpoint blockade.A review of vaccine clinical trials for non-small cell lung cancer.Promises and limitations of murine models in the development of anticancer T-cell vaccines.Weak proinsulin peptide-major histocompatibility complexes are targeted in autoimmune diabetes in mice.Quantitative theories of T-cell responsiveness.Identification of T-cell epitopes for cancer immunotherapy.Mobilizing the low-avidity T cell repertoire to kill tumors.Prospects and challenges of building a cancer vaccine targeting telomerase TARP vaccination is associated with slowing in PSA velocity and decreasing tumor growth rates in patients with Stage D0 prostate cancer.Improving T cell responses to modified peptides in tumor vaccines Is telomerase a viable target in cancer?Targeting antitumor CD4 helper T cells with universal tumor-reactive helper peptides derived from telomerase for cancer vaccine.Towards in silico design of epitope-based vaccines.Analogue peptides for the immunotherapy of human acute myeloid leukemia.Identification of a novel PD-L1 positive solid tumor transplantable in HLA-A*0201/DRB1*0101 transgenic mice Type 1 diabetes associated HLA-DQ2 and DQ8 molecules are relatively resistant to HLA-DM mediated release of invariant chain-derived CLIP peptides Hierarchy of alpha fetoprotein (AFP)-specific T cell responses in subjects with AFP-positive hepatocellular cancer.Cyclin D1 as a universally expressed mantle cell lymphoma-associated tumor antigen for immunotherapy.Enhanced major histocompatibility complex class I binding and immune responses through anchor modification of the non-canonical tumour-associated mucin 1-8 peptide.Mannan-modified adenovirus as a vaccine to induce antitumor immunity.EphA2 as a glioma-associated antigen: a novel target for glioma vaccines.Prevention of diabetes by manipulation of anti-IGRP autoimmunity: high efficiency of a low-affinity peptide.Targeting cryptic epitope with modified antigen coupled to the surface of liposomes induces strong antitumor CD8 T-cell immune responses in vivo.

P2860

Q24652592-D16D0CA6-DB1E-4FA3-8446-4038C4118B3A Q26738680-116A06FF-4984-4E0D-A0C1-796F4213B8C4 Q30418879-2B07D1FE-5405-4002-9436-3756B0D68069 Q33276030-22D221EC-64DC-4E1B-9C12-B5450CD51704 Q33522216-3D15D98C-81D6-4D52-AEFE-6255BF4847B2 Q33897405-93CE23DE-9D09-483F-A09F-285F7C8D7F45 Q34878113-17C65570-4F31-4DF4-BBBF-82D8C3F4E084 Q35125382-83C336E0-5153-472C-8B82-BDE52CF4750B Q35588533-31C89085-B7ED-4E07-86EB-7FE53C373E3C Q35663042-11CE634F-4094-4BD6-BD17-EDE82AE04844 Q35848862-BC47908A-F6CE-43E1-B18B-15588A1F268C Q36194073-36B0F9D8-2F67-4F38-88AE-5F1AF1A2A994 Q36331221-C2BA8404-130B-4765-88F7-91093D0E0885 Q36350565-5861E4CD-6C37-486C-9578-7BC07D35C1E0 Q36593753-82AC9600-6D5C-4878-8777-E272FB66C0F5 Q36600251-8A7964FA-D519-4767-AAFC-B5739FDA377E Q36610764-B86282B8-CA11-403F-8EBF-34C9B8615493 Q36653524-F98586D3-30FF-4E9E-AD91-86C40AED7CF8 Q36675454-819EB591-A4B0-4805-8755-72EC247A510F Q36684482-462737A5-DF85-490D-B601-8EB647FE6CFC Q36756575-BE757C52-8D40-46DB-BFC9-B26F8B2CC27B Q36762522-29DA86CF-31F1-4501-814A-990C40FAE0F3 Q36870592-1DFBCE13-A012-4EAA-9F74-ECB17EB23FF6 Q36891310-91B84355-77E5-4834-A683-D9D30A5D3342 Q36918394-5131BCEF-D6CD-484C-8304-70DB3BA65025 Q37224581-0945BF1E-67F4-462D-BDFC-FD8404F0AC3E Q37634253-222AC345-10A9-4EF4-BFD0-40B69D072210 Q37908470-2C0F5293-55C3-4851-9A6B-1C306DAB2A55 Q38077405-79C0FAF5-168C-46B1-AFE1-C10453CC1B38 Q38088325-4519501D-584D-4AF8-95A6-4BC5CEF40FF0 Q38599586-18669FF7-13FA-4E58-8F2F-DBFCF7137DD5 Q38706572-150A04CF-F2EA-426C-9BDB-A7546C0C7619 Q38808868-5ED8BD3F-2A88-4AB7-9493-A8B97B6B65F0 Q39285795-553C483C-E92A-44A9-97C8-8FE053A46ABB Q39882401-13982163-4F28-42F8-B047-48D8EC72913C Q40215247-5EFA175E-2350-4623-819A-FC4E9EF680E8 Q40243921-AD845A95-60F2-4CCA-8AC7-C045D3F0D3AD Q40365151-128A5B88-6CD5-4AB4-A407-6C677A4035D4 Q40418904-4796446E-1DB2-4DD5-80E8-A91D67BE331F Q40510640-637E79A7-B9E3-4160-9898-75124BC4EF8E

P2860

High vaccination efficiency of low-affinity epitopes in antitumor immunotherapy.

http://www.wikidata.org/entity/Q35631830

description

2004 nî lūn-bûn

@nan

2004年の論文

@ja

2004年論文

@yue

2004年論文

@zh-hant

2004年論文

@zh-hk

2004年論文

@zh-mo

2004年論文

@zh-tw

2004年论文

@wuu

2004年论文

@zh

2004年论文

@zh-cn

name

High vaccination efficiency of low-affinity epitopes in antitumor immunotherapy.

@ast

High vaccination efficiency of low-affinity epitopes in antitumor immunotherapy.

@en

type

label

High vaccination efficiency of low-affinity epitopes in antitumor immunotherapy.

@ast

High vaccination efficiency of low-affinity epitopes in antitumor immunotherapy.

@en

prefLabel

High vaccination efficiency of low-affinity epitopes in antitumor immunotherapy.

@ast

High vaccination efficiency of low-affinity epitopes in antitumor immunotherapy.

@en

P1433

Q35631830-00961519-5087-465A-B4F9-D992C22E8D2C

P1476

Q35631830-AA0AA114-70DB-49D1-A7BF-E0D9CA1BBD0A

P2093

Q35631830-031AE4FE-6E70-40DE-B685-B32E311D404F

Q35631830-2B999F79-A7C3-46B7-ACF8-741255A2A55E

Q35631830-4886CA1C-3C3B-4480-BC69-CB4EE6FD8E66

Q35631830-5CCF6C8F-DBBD-49A5-8054-CF184A6D88FD

Q35631830-674041E9-136C-4BD1-88D8-7CA93C93470B

Q35631830-75B3982C-7B8D-4B4F-A31B-6933966407B1

Q35631830-A6A1E1E6-6632-437D-8BA4-E6F10664C0A0

Q35631830-AB318552-B2E0-48E9-900B-23EB50F15454

Q35631830-BF239466-A0F7-42F2-989E-66FE59A76539

Q35631830-E16BE7FE-BC8D-46BF-B773-752D926CC2D5

P2860

Q35631830-01FD7E54-AE06-4CAA-BD2D-3F687ABD0BCD

Q35631830-12F5FD1B-8823-4CB3-9E2C-14CD60DAB229

Q35631830-13BE8567-5D5D-426D-A172-9B03CE25B4C9

Q35631830-13FDA4A6-A191-40AC-9CCC-D3C33DF1C213

Q35631830-189B0B65-FD8E-4179-B303-9A9044734BEE

Q35631830-2A4EBD32-CEEB-4518-898F-E1EEECBC04CB

Q35631830-2B08E456-B1FD-4BDB-B85A-19A339F9F262

Q35631830-2F85FBF8-001C-4A73-A7A5-A7AD207B2386

Q35631830-4DEC5DDB-58D4-496E-B6E7-CBD68BDB6310

Q35631830-56D9A55E-E60C-46FA-99BA-22638DF2886A

P304

Q35631830-66DA0629-188D-4522-B838-2FCE4C09E71D

P31

Q35631830-A376043C-EABE-43DB-9DDD-A9CE56226B65

P356

Q35631830-1B3B92BE-0DCB-4035-84B2-2155C3BF53F5

P407

Q35631830-2771DEA9-C322-479D-A55D-2E0DFAF3D716

P433

Q35631830-06F3B152-7781-4DB1-8B50-CDDF4491D058

P478

Q35631830-48EE1D27-F270-4A0A-9CAC-0E712EF7BCA1

P50

Q35631830-B10E37F1-4BE3-47F6-84CC-472FD01F0A00

Q35631830-CB086722-3727-4D7C-ABFE-B6EFAEFC3B9D

Q35631830-E1AEEE1A-E8F4-4445-9A09-475078F17343

Q35631830-F021C37B-86E0-4DFE-B719-12DC8CC4681C

P577

Q35631830-4FBFC2CA-3CAA-4DE8-A681-3231BE342039

P698

Q35631830-B6F7C862-D43B-4D8E-BD52-EE30F717AEEE

P921

Q35631830-3B28309C-2B3D-4DE5-8A63-4A5146ECE006

P932

Q35631830-5CE28531-728F-42FA-979E-F33A25E3B4AD

P356

P1433

Journal of Clinical Investigation

P1476

High vaccination efficiency of low-affinity epitopes in antitumor immunotherapy

@en

P2093

François A Lemonnier

http://www.w3.org/2001/XMLSchema#string

Hüseyin Firat

http://www.w3.org/2001/XMLSchema#string

Isabelle Miconnet

http://www.w3.org/2001/XMLSchema#string

Kostas Kosmatopoulos

http://www.w3.org/2001/XMLSchema#string

Olivier Faure

http://www.w3.org/2001/XMLSchema#string

Paule Opolon

http://www.w3.org/2001/XMLSchema#string

Pedro Alves

http://www.w3.org/2001/XMLSchema#string

Philippe Guillaume

http://www.w3.org/2001/XMLSchema#string

Robert H Vonderheide

http://www.w3.org/2001/XMLSchema#string

Salem Chouaib

http://www.w3.org/2001/XMLSchema#string

P2860

The telomerase catalytic subunit is a widely expressed tumor-associated antigen recognized by cytotoxic T lymphocytes

Eradication of established murine tumors using a novel cell-free vaccine: dendritic cell-derived exosomes

Self-tolerance to the murine homologue of a tyrosinase-derived melanoma antigen: implications for tumor immunotherapy

Degradation of cell proteins and the generation of MHC class I-presented peptides.

A fresh look at tumor immunosurveillance and immunotherapy.

The self-directed T cell repertoire: its creation and activation.

Developmental and tissue-specific regulation of mouse telomerase and telomere length.

Scheme for ranking potential HLA-A2 binding peptides based on independent binding of individual peptide side-chains.

Adjuvant immunotherapy for solid tumors: from promise to clinical application.

Vaccination with a recombinant vaccinia virus encoding a "self" antigen induces autoimmune vitiligo and tumor cell destruction in mice: requirement for CD4(+) T lymphocytes.

P304

425-433

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1172/JCI200419418

http://www.w3.org/2001/XMLSchema#string

P407

P433

3

http://www.w3.org/2001/XMLSchema#string

P478

113

http://www.w3.org/2001/XMLSchema#string

P50

Stéphanie Graff-Dubois

Annelise Bennaceur Griscelli

P577

2004-02-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

14755339

http://www.w3.org/2001/XMLSchema#string

P921

P932

324537

http://www.w3.org/2001/XMLSchema#string